Good day, welcome to the Myomo Q2 2021 financial results conference call. All participants will be in listen-only mode. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded. I would now like to turn the conference over to Kim Golodetz with LHA. Please go ahead. Thank you, operator, and good afternoon, everyone. Welcome to the Myomo Q2 2021 financial results conference call. Earlier today, Myomo issued a news release announcing financial results for the three months ended June 30th, 2021. If you would like to be added to the company's email distribution list to receive future announcements, please register on the company's website at myomo.com, or call LHA in New York at 212-838-3777 and speak with Carolyn Huston-Curran. With me on today's call from Myomo are Paul Gudonis, Chief Executive Officer, and Dave Henry, Chief Financial Officer. Before we begin, I'd like to caution listeners that statements made during this conference call by management, other than historical facts, are forward-looking statements. The words anticipate, believe, estimate, expect, intend, guidance, outlook, confidence, target, project, and other similar expressions are typically used to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and may involve and are subject to certain risks and uncertainties and other factors that may affect Myomo's business, financial condition, and operating results, including the impact of the ongoing COVID-19 pandemic. These and additional risks, uncertainties, and other factors are discussed in the risk factors and other qualifications contained in Myomo's filings with the Securities and Exchange Commission, including the Form 10-Q for the quarter ended June 30th, 2021, which was filed earlier this afternoon. Actual outcomes and results may differ materially from what's expressed in or implied by these forward-looking statements. Except as required by law, Myomo undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call. It is now my pleasure to turn the call over to Paul Gudonis, CEO of Myomo. Paul, please go ahead. Thank you, Kim. Good afternoon, everyone, and thank you for joining us today. After I provide a business update, Dave will review our Q2 financial results and discuss our financial outlook. Following the financial update, I'll give some closing remarks and then we'll take your questions. As the Q2 began, it was heartening to see the large number of vaccinations and the significant drop in the number of COVID-19 cases in the U.S., and unlike a year ago, our operations have returned to a more normal pre-pandemic environment. Product deliveries are up significantly from this time a year ago, and our staff is able to gather in person once again to work in our new offices in Boston while others continue to work remotely or in a hybrid mode. We're hopeful that the recent surge in cases will soon be under control, and we expect that our business will continue to operate without disruption. Our overarching goal as a company is to improve the lives of people with upper limb paralysis. At the same time, our focus is on increasing MyoPro sales and benefiting from operating leverage as we scale the business towards cash flow breakeven. We recognized revenue on 80 units during the Q2, up 233% from the pandemic-constrained period a year ago and up 23% sequentially from Q1. More importantly, the number of authorizations and orders were a record 138 MyoPros, which is more than double the number in Q1 and represents nearly $5 million in potential revenue, which will be recorded as these orders are delivered and the insurance payments are received. As a result of the growth in these key metrics, we're reporting revenues for the quarter of $3.1 million, more than triple last year's Q2 and up 33% sequentially. The factors driving this growth include the following. A large number of patient candidates in our pipeline as we started the year with more than 700 patients in the insurance authorization process. Increased direct-to-patient marketing, which led to a record number of interested candidates in Q1 and over 650 in total in the first six months of the year. Greater success in obtaining insurance authorizations for patients with approvals from a growing number of payers. Revenue growth in our international operations, especially Germany, where more statutory health insurance payers are covering the cost of the MyoPro. Our channel strategy is three-pronged. First, it consists of our own direct billing operations, where we bill insurers directly and provision the MyoPro with our own clinical staff. Second, we also support orthotics and prosthetics providers in the U.S. and international markets who source their own MyoPro candidates and are responsible for provisioning and billing. Third, we're focused on VA medical centers for veterans and their care. During the Q2, revenue from the direct billing channel represented 74% of total revenue, compared with 49% a year ago. Our gross margin has also improved with this emphasis on the direct billing approach, as Dave Henry will describe in a moment. Backlog is defined as MyoPros that have been authorized by payers but are either in the process of being delivered to users or are awaiting payment to us. Our backlog increased to 160 units at quarter end. This is up from 118 units at the end of Q1, reflecting the large number of insurance authorizations received during the quarter and representing patients who are in the queue to receive their MyoPros. After the very strong growth in the patient pipeline in Q1, we added 277 new candidates in Q2 and had an ending pipeline of 898 patients as of June 30th. We use social media platforms and search engine marketing to inform paralyzed individuals and their families about the benefits of the MyoPro. At the beginning of the quarter, we did feel the impact of the Apple versus Facebook privacy war on our lead generation. As you may be aware, Apple implemented new software features in its iPhone operating system to reduce the amount of web tracking that is conducted by Facebook and other platforms. Facebook, for example, relies on data about where users are going on the internet for medical information, et cetera, to enable advertisers like Myomo to better target their intended audience. We adjusted our marketing strategies to this change, working with our advertising agency to develop other means of reaching potential candidates, and also increasing our ad spending to expand our reach. As a result of these changes, our weekly lead generation is back up to where it was in the Q1 when we had very strong growth in new candidates. We work with patients in the pipeline to obtain a MyoPro prescription and supporting clinical documentation from their physician. It typically takes several months for these candidates to work their way through the insurance process to an authorization and eventual delivery and payment. We expect that between 10% and 20% of pipeline patients drop out each quarter due to personal patient issues and/or lack of insurance approval. We take this into account in our planning. Since HCPCS codes for the MyoPro were issued in 2019, we've seen an increase in patient access to our devices, with more payers covering the MyoPro on a case-by-case basis for their beneficiaries. In particular, we've experienced strong growth among Medicare Advantage plans covering the MyoPro. The huge increase in insurance authorizations in the quarter is also due to our Chief Medical Officer's outreach to physicians and payers, including an online clinical education program about the MyoPro. Since Dr. Coleman joined us last fall, many more physicians are documenting the medical necessity for their patients. In the past few months, we've had over 20 insurance plans cover their first MyoPro, including state Medicaid plans in Arizona, Nevada, Utah, and New Jersey, Blue Cross Blue Shield plans in Maryland, New York State, and Rhode Island, multiple Medicare Advantage plans such as CarePlus Florida and Stanford Health Care, and commercial plans including Fallon Select. For patients covered by Part B standard Medicare, we applied for a benefit category change from DME rental to custom fabricated orthosis or brace based on a new rulemaking process that was underway at the Centers for Medicare and Medicaid Services at the beginning of the year. With the change in administration, the delay in appointing a new CMS head, and the continued focus on COVID-19 inside the agency, nothing has happened with this proposed rule so far. We withdrew our code change amendment, and we will follow up with CMS if and when new rules about correcting devices' benefit category are implemented. In the meantime, we continue to engage with private and government insurance plans with increasing success, as I described earlier. In more recent weeks, we announced that we'd received word that the Healthcare Quality Association on Accreditation, or HQAA, certifying that Myomo meets the accreditation requirements under the Social Security Act and federal regulations. This accredited provider status is an important step following on to our receiving the HCPCS codes and was required by the Centers for Medicare and Medicaid Services as a condition of our Medicare provider authorization. It's an important step to bringing the MyoPro to patients whose quality of life can benefit from its use. I'd like to mention that we are like many other companies that rely on technology components to manufacture our devices. While we have been able to source all the necessary items so far this year, we're experiencing some extended lead times in some cases and some cost increases as alternate parts are sourced. We're closely monitoring our supply chain so that orders are fulfilled on time and there's no impact on our patient deliveries. Our international business, primarily in Europe, is an important avenue for growth. During the Q2, international sales represented approximately 10% of our revenue. We have a growing pipeline in Germany, the U.K., and Italy. We were also able to have our joint venture formation documents certified by U.S. and Chinese government agencies during the Q2, thus enabling Ryzur Medical, our JV partner in China, to proceed with the filings necessary to establish the business entity in China. We expect that process to be completed during the Q3. As a reminder, Myomo will hold a 19.9% equity interest in the joint venture. We'll also receive an upfront license fee and annual license payments for the next 10 years. The joint venture launch preparations are ongoing and will take some time over the course of this year. I'd also like to highlight some recent changes to our corporate governance. I'm pleased to welcome Dr. Milton Morris to Myomo's board of directors. Shareholders elected Dr. Morris in June. He's an experienced medical device executive and entrepreneur who's developed and launched new medical technologies and scaled up operations, and we look forward to his contributions to our company strategy and growth plans. I also want to mention that at the end of the Q2, we were delighted that Myomo stock was added to the Russell Microcap Index. The addition reflects the work that we've been doing to grow the company's valuation to a size that permits inclusion in this group of smaller emerging growth stocks. Membership in the index will be in place for one year. I'll turn the call over to Dave Henry, our CFO, to review our financial results in more detail. I'll then come back and provide some additional updates and comment on our plans for the rest of the year. Dave? Thank you, Paul. Turning now to our Q2 financial results. Revenue in the Q2 of 2021 was $3.1 million, and this is up 262% over the prior year Q2, which of course was adversely impacted by the COVID-19 pandemic. I'd like to point out that along with a larger number of MyoPro revenue units, we also had a higher average selling price, both year over year and on a sequential quarter basis. A higher ASP contributed to the revenue growth and also reflects the success we're having with our direct billing channel and our marketing efforts. More specifically, we recognized revenue on 80 MyoPro units in the Q2 of 2021, an increase of 233% compared with the Q2 of 2020. We benefited from a record number of fill units in the Q2, which are revenue units for which the authorizations and orders were received in the same quarter. Of the 80 revenue units, 38 were fill units led by the strength in VA and international channels. Of those, nearly half were direct billing units. Recall that for certain insurers where collection history has been established, we're taking revenue at delivery. This is an example of how we are able now to accelerate the revenue cycle in the direct billing channel. Our backlog of units consists of insurance authorizations received but not yet converted to revenue. As of June 30th, 2021, our backlog was 160 units. Ending backlog reflects 138 authorizations and orders in the Q2 and 16 patients who exited the backlog without converting to revenue. Approximately 88% of the quarter-end backlog is comprised of direct billing candidates, compared with 92% at the end of the Q1. As Paul mentioned, the reimbursement pipeline at June 30th was 898 MyoPro units, which reflects 277 additions to the pipeline during the quarter and 181 drops, which was 19% of the pipeline entering the Q2. As a result of our marketing efforts and continued success in obtaining authorizations from new insurers, more than 80% of the patients in the pipeline at the end of the Q2 are covered by insurers that have previously reimbursed or agreed to reimburse for the MyoPro. Gross margin for the Q2 of 2021 was 71%. This is up from 51% in the year ago quarter. The year-over-year increase primarily reflects a higher average selling price, again reflecting the shift to our direct billing channel. There were 86 MyoPro delivered to patients in the Q2 for which we recorded cost of goods sold compared to 80 revenue units. This, combined with higher warranty reserves and material price increases on certain constrained components, impacted gross margin in the quarter. As Paul mentioned, we're experiencing longer lead times on certain materials, but we currently believe that we have access to a continuous supply of materials and components. Operating expenses for the Q2 of 2021 were $4.8 million. This is up 46% compared with the same quarter a year ago and primarily reflects higher compensation and advertising costs. The operating loss for the Q2 of 2021 was $2.6 million, and this continued to narrow from $2.8 million a year ago and $2.9 million in the Q1 of this year. Net loss for the Q2 of 2021 was $2.6 million or $0.46 per share, compared with a net loss of $3.3 million or $1.12 per share for the Q2 of 2020 and $3 million or $0.57 a share for the Q1 of this year. Adjusted EBITDA for the Q2 of 2021 improved to a negative $2.2 million, which compares with a negative $2.7 million for both the Q2 of 2020 and the Q1 of 2021. Cash and cash equivalents as of June 30th, 2021 were $13.8 million. Cash used by operations was $3.4 million in the Q2 and includes the payment of 2020 incentive compensation. Turning briefly to our year-to-date financial results. Revenue for the six months ended June 30th, 2021 was $5.4 million, up 191% over the prior year period. The year-to-date operating loss and net loss attributable to common stockholders were $5.5 million and $5.6 million respectively, compared with an operating loss of $6.3 million and a net loss attributable to common stockholders of $7.8 million for the six months ended June 30th, 2020, respectively. Net loss attributable to common stockholders for the first six months of 2020 includes a charge of $500,000 related to partial extinguishment of the company's convertible note and approximately $700,000 for a deemed dividend on the price reset of certain warrants. Year-to-date adjusted EBITDA improved to a negative $4.9 million, compared with a negative $6 million in the same period a year ago. I'll now address our near-term expectations. Cash use in operating activities is expected to decrease sequentially in the Q3 of 2021 due to a lower working capital requirement. We continue to believe our existing cash is sufficient to fund operations well into the H2 of 2022. We continue to expect lower cash utilization in the H2 of 2021 compared with the H1, with the goal of full year 2021 cash usage to be below full year 2020 cash usage. With our H1 results, we're nicely on track to achieve this goal. With a record number of insurance authorizations and orders during the Q2 and a robust backlog of 160 units as of June 30th, along with a growing list of insurance companies reliably paying for the MyoPro, we expect to be able to deliver solid year-over-year growth once again in the Q3. With that overview, I'll turn the call back to Paul. Thanks, Dave. Well, to reiterate, the pillars of our growth strategy are to increase our marketing activity to generate additional patient candidates for the MyoPro, to increase the number of insurance authorizations by working with payers and physicians to expand access to the MyoPro, to emphasize our direct billing channel in the U.S. for greater revenue and margin per unit, and to expand into international markets to tap into additional patient demand. Adding to these growth initiatives is our investment in product development, as well as our investment in clinical research to demonstrate the positive health outcomes of using a MyoPro. Several independent studies are pending publication this year, and new studies are underway that are expected to support our marketing and reimbursement efforts, including an outcomes registry and additional RCTs, which we expect to be key components of our body of scientific evidence. We also look forward to a number of near-term catalysts, including an upcoming announcement about the adult version of the MyoPro and resuming development and launch of the MyoPal orthosis for children. This concludes the formal part of our presentation, operator. We're now ready to open up the call to questions. We will now begin the question and answer session. To ask a question, you may press star then one on your telephone keypad. If you are using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star then two. At this time, we will pause momentarily to assemble our roster. Before we take the first question, I want to mention that we are available for virtual and a return to in-person investor meetings, so please contact LHA Investor Relations to set up a time. Their contact information is on today's news release. We'll also be participating in several virtual and in-person conferences during the H2 of the year, including H.C. Wainwright's 23rd Annual Global Investment Conference, Colliers International, and the MicroCap Rodeo in Austin, Texas in October. Some of these will be a hybrid conference, both in person and virtual, and we're very excited that our plans call for in-person participation in New York City. Okay, operator, we're ready for the first question whenever you are. Thank you. The first question comes from Scott Henry with Roth Capital. Please go ahead. Thank you, and good afternoon. I just had a couple questions as I look at the model. Strong Q2, so I just wanted to get into some of the drivers there. For starters, pipeline adds, I think it was 386 in Q1, 277 in Q2. Both good numbers, but obviously Q1 a lot stronger than Q2. I think you mentioned that that will be bouncing back. I guess the question is, should I think Q3 will look a lot more like Q1 or Q2? I think Q3 will look closer to Q1, Scott. We've already had, to this point in the quarter, over 100 new patient candidates enter the pipeline, meaning they came in as a lead, they've been medically evaluated, and now they're in the insurance process. I think we'll see an upswing above the Q2 numbers. Okay. Do you think, and I'm talking about the pipeline adds, closer to the Q1, or do you think maybe you can get all the way into the 300s for pipeline adds in Q3? Well, we're just over 100, about one third of the way through the quarter. I think we'll do better than Q2 and somewhere in that range between Q2 and Q3. We'll see how it goes over the next two months. Okay, great. Thank you for that color. Then the other number that moves around a little bit is the pipeline that is lost to erosion. Sometimes it's 13%, 12%, sometimes it's 20%. I typically think of it being around 15% with volatility in either direction. Is that a safe assumption, or should I be thinking of that number higher, like the last couple quarters, or lower? Hey, Scott, it's Dave. Yeah. The drops were about 19% of the beginning pipeline. I still think somewhere between 15% and 20% is a good number. One thing I will say, just to reiterate, that of the pipeline, that at the end of the Q2, more than 80% represents patients with insurers who have authorized for the device. It's a pretty high quality pipeline, and we just hopefully we'll see the drops moderate as we go. The process is still long and the top reason for patients dropping out is because we can't get a hold of them again. Okay. All right. That's fair enough. That's helpful. I appreciate the color, Dave. Final question is just the pricing moved back up. We've kind of seen that number before, but then it dropped down. Do you think the 2Q pricing is indicative of going forward, or might we see it pull back a little bit? Just any color you can provide. I would continue to assume that from a modeling standpoint, that the average selling price is around $35,000. Reimbursements can vary from anywhere from the $20,000s if it's an O&P provider, all the way up to $90,000, which we've had before for some of the direct billing reimbursements. It's a wide range there. Given that, I would just continue to assume like a mid-$30,000s kind of ASP. Okay, great. Thank you for taking the question, guys. Sure. The next question comes from Jim Sidoti of Sidoti and Company. Please go ahead. Hi, good afternoon, Paul and Dave. Thanks for taking the question. A lot's happened with CMS over the past couple of years. You were certified as an authorized provider. You got your HCPCS code. You've received accreditation. You pulled back the application as you're waiting on CMS to make up their final regulations and get their house in order. How do we think about this going forward? How many more steps do you think there'll be before you get that code quantified? In our discussions with CMS, which have been ongoing ever since we got the HCPCS codes, you may recall last year, toward the end of last year, they put out a proposed rulemaking, which would enable companies who feel like their devices are in the wrong category, apply for a benefit category change. That's what we did. However, that rulemaking was never finally approved. I think once the administration changed in January, everything just stalled over there, and it wasn't until recently that a new administrator was appointed. What we understand is that CMS will propose that rulemaking again in the next 4- 6 weeks, and then it takes a while to get comments and to decide on it. If that happens, then we will certainly look to it as an opening there to correct that benefit category so that Part B patients get to get access to this. In the meantime, ever since we got those HCPCS codes back in January 2019, we've been able to address these needs of a large and growing population of Medicare Advantage plans. In fact, I saw some recent data that showed that Medicare Advantage plans in the last couple of years have gone from 35%- 39% of seniors. That means hundreds of thousands of additional Medicare-eligible patients have opted for Medicare Advantage plans, and we're getting a number of those to reimburse for the device. That's a positive trend, even if this Part B drags on for a while. That was my next observation. You tripled revenue in the quarter. I think I heard you say you got 20 new insurance providers to reimburse the device in the quarter. How critical is it to get these codes quantified, or can you continue to grow without it? I think we've got strong growth prospects in front of us. Just based on what we're doing on a case-by-case basis, our Chief Medical Officer is now actively engaging with these commercial payers and some of the state Medicaid plans where we've gotten successful payments over time. Once there's a large enough bolus of patients that have been approved and there's others in the queue, you get the attention of the medical directors of these payers. It takes a while to get those meetings. We expect to have the first several of those meetings in the fall. You present your case for coverage. You get support from local physicians and other clinical specialists in the area. Pending the medical director's coverage decision, then you go over to the business side of the house to negotiate a contract. It's not a quick process, but it's one that we're making steady progress on, and hopefully, by next year sometime, we would have some of these commercial contracts in place. In the meantime, we continue to get repeat orders. As Dave mentioned, over 80% of our pipeline are with payers that have already paid for MyoPro or have agreed to under a single case agreement. We expect we will continue to focus on that large number of patients that have those insurance plans and keep expanding the number of ones that are covering this. Okay. The last question from me is on seasonality. In the medical device space, some of the more mature companies typically see a slowdown in the summer quarter as folks go on vacation. You guys have been growing so fast that that hasn't been a factor for you up until now. Do you think you're at a point where you'll start to see the typical seasonality trends that some of the other companies see? Well, we do believe our guidance is for strong year-over-year revenue growth in the Q3, and we have a backlog comparable to Q4 of last year. Recall Q4 of last year, we had record revenues. I think we have the opportunity here for a very good quarter in Q3 as well. Okay. Thank you. The next question comes from Benjamin Haynor with Alliance Global Partners. Please go ahead. Good afternoon, gentlemen. Thanks for taking the questions. First off for me, I know that the backlog and the revenue units and authorizations had really solid performance here during the quarter. I also realize how pipeline kind of gets the attention just because it's the quote unquote, "top of the funnel." Did I hear you correctly that now more than 80% of the pipeline is with insurers that have reimbursed the device previously? That's right. Can you give us a sense of what that looked like a year ago? I'd have to get back to you on that. I don't have that number handy. A ballpark would be helpful as well. Is it 50%, is it 10%? I would say qualitatively, it's better because our marketing strategy over the past several quarters now is to try to, through the targeting on social media, try to target those payers with insurers that would reimburse the device. That includes Medicare Advantage plans and other commercial plans in the past. This is a purposeful result of the things that we've been doing over the past several quarters. The exact number I don't have, but I'm going to venture to guess it's higher than what it was a year ago. Well, the other thing too, Ben, it's Paul. As I mentioned, we've been continuing to get more and more payers become first-time MyoPro reimbursers. That number of payers that are reimbursing for the device continues to grow quarter after quarter. Okay. That makes sense. Everything should have kind of a virtuous cycle where the pipeline continues to improve if you keep executing like you have been. Yeah, that's right. More patients in the pipeline and more of these patients with payers that are covering the device. Makes sense. The 38 of the 80 revenue units being ones where the orders and authorizations occurred during the quarter. You mentioned that's a record. Is it a record both on an absolute basis of 38 units, but also on a percentage basis, being whatever, 48% or so of the revenue units were ordered and authorized during the quarter? What's the right way to think about that? Well, on a percentage basis, probably not. Our primary channels were O&P and VA. A lot of that was turns business. Since we really started emphasizing direct billing a couple of years ago, it's a record in terms of absolute number. In terms of percentages, probably going back to when we started doing direct billing more extensively, it's a record for that time period as well. Okay. The reason we had so many, and just to reiterate, of the 38 bill units in the quarter, half of those were direct billing. That's the result of being able to recognize revenue upon delivery for those insurers where we have sufficient collection history. We don't have to wait until payment to recognize revenue. If I'm understanding you correctly, then, if you take out the O&P units and let's call it 60 units, and 19 or so of those were direct billing patients that were ordered and authorized during the quarter. It's like 19 of 60, so roughly a third? Yeah. 19 of the 60 were the other channels. Okay. O&P and VA. That's what those were, yes. Okay. I guess last one for me, and then I'll jump back in the queue. What proportion of insurers have you established of the quarterly revenue here? Have you established a track record, and how do you expect that to grow? Does that make sense? Yeah. Those insurers that we have sufficient collection history on represent about 40% or so of our revenue. Over time, we would look for that to grow as we expand the list of payers that we have sufficient collection history on. Okay. That's exactly what I was looking for. Thank you very much, gentlemen, and congrats on the quarter. Thank you. Thanks, Ben. Again, if you have a question, please press star then 1. The next question comes from Edward Woo with Ascendiant Capital. Please go ahead. Yeah. Congratulations on the quarter, guys. Also congratulations on the growth in Europe. You mentioned that it was 10% of revenue. What do you think it could be long term? You think it could get to 50%? Well, the U.S. market is growing very strongly for us. We've got strong growth in Europe. Whether or not it can take more global market share of our revenue, that will depend over time. Clearly, with China coming on board, more of our revenue will start to come from international. We'll have to make investments to open up other markets to really move that percentage up. We're satisfied right now if that's in the range of 10%-15% of our revenue, because again, overall, we've been growing north of 100% a year. There are other markets. There are some markets in Europe that have been inaccessible up till now. We still have 10% of our revenues coming from Europe. As things with the pandemic start to wane a bit and more countries open up, like the U.K. or Italy, and others that we have established good relationships with, we would hope that hopefully the international part of the revenues will continue to grow. Will you be able to use the same game plan that you have in the U.S., focus on direct and also a lot of social media marketing? Would that be applicable in Europe as well as Asia? Well, somewhat. In these other countries, we go through orthotics prosthetics practices because they are licensed in the country. They have relationships with the various payers. They speak the local language, of course. It's much more difficult for us to establish our own clinical operation in these other countries, but we're very satisfied working with these O&P partners. We do have now, for example, a German website. We are taking some of the marketing activities approach from the U.S., starting to do that with social media in places like Germany. As a result, we're going to take best practices from here to Europe, but we can't replicate exactly what we do here in the United States. Great. Well, thank you for answering my question, and good luck. All right. Thank you, Edward. This concludes our question and answer session. I would like to turn the conference back over to Paul Gudonis for any closing remarks. Thank you, operator. Well, in closing, we're optimistic that the economy here and in other countries will continue to open up, and that despite the current increase in cases due to the Delta variant, the pandemic will abate over the course of the year. Assuming that's the case, we expect to accelerate the additions to our patient pipeline and to record strong annual revenue growth for the fifth year in a row. We're addressing a very large unmet need with a life-changing solution while contributing and continuing along the path to our milestone of break-even cash flow from operations. Once again, thanks for your time and for your interest in Myomo. Have a good evening. The conference has now concluded. Thank you for attending today's presentation.